[go: up one dir, main page]

MX9603199A - Antagonistas de receptores a endotelina. - Google Patents

Antagonistas de receptores a endotelina.

Info

Publication number
MX9603199A
MX9603199A MX9603199A MX9603199A MX9603199A MX 9603199 A MX9603199 A MX 9603199A MX 9603199 A MX9603199 A MX 9603199A MX 9603199 A MX9603199 A MX 9603199A MX 9603199 A MX9603199 A MX 9603199A
Authority
MX
Mexico
Prior art keywords
receptors antagonists
endotheline
endotheline receptors
antagonists
compounds
Prior art date
Application number
MX9603199A
Other languages
English (en)
Inventor
Werner Mederski
Mathias Osswald
Dieter Dorsch
Claudia Wilm
Claus J Schmitges
Maria Christadler
Original Assignee
Merck Patent Gmbh
Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Haftung filed Critical Merck Patent Gmbh
Publication of MX9603199A publication Critical patent/MX9603199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)

Abstract

Los nuevos compuestos de formula I: donde -Y-Z-, R1, R2, R3, R4 y R5 tienen los significados en la reivindicacion 1, y las sales, de estos compuestos, presentan propiedades antagonistas de los receptores de endotelina.
MX9603199A 1995-08-02 1996-08-02 Antagonistas de receptores a endotelina. MX9603199A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19528418A DE19528418A1 (de) 1995-08-02 1995-08-02 Endothelin-Rezeptor-Antagonisten

Publications (1)

Publication Number Publication Date
MX9603199A true MX9603199A (es) 1997-07-31

Family

ID=7768528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603199A MX9603199A (es) 1995-08-02 1996-08-02 Antagonistas de receptores a endotelina.

Country Status (16)

Country Link
US (1) US5731321A (es)
EP (1) EP0757039A1 (es)
JP (1) JPH0940649A (es)
KR (1) KR970010746A (es)
AR (1) AR004675A1 (es)
AU (1) AU705959B2 (es)
BR (1) BR9603252A (es)
CA (1) CA2182469A1 (es)
CZ (1) CZ224096A3 (es)
DE (1) DE19528418A1 (es)
HU (1) HUP9602127A1 (es)
MX (1) MX9603199A (es)
NO (1) NO963213L (es)
PL (1) PL315479A1 (es)
SK (1) SK100296A3 (es)
ZA (1) ZA966552B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815870A3 (en) * 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7825131B2 (en) * 2003-09-23 2010-11-02 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009023655A1 (en) * 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Quinazolinedione chymase inhibitors
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
NZ585226A (en) * 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
GB9115153D0 (en) * 1991-07-12 1991-08-28 Patel Bipin C M Sol-gel composition for producing glassy coatings
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
US5565472A (en) * 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
DK0617001T3 (da) * 1993-03-19 2000-04-17 Merck & Co Inc Phenoxyphenyleddikesyrederivater
JPH06340658A (ja) * 1993-04-08 1994-12-13 Kyowa Hakko Kogyo Co Ltd ベンゾイミダゾール誘導体
EP0723449A1 (en) * 1993-08-06 1996-07-31 Smithkline Beecham Corporation Endothelin receptor antagonists
DE4341663A1 (de) * 1993-12-07 1995-06-08 Basf Ag Anellierte 2-Oxopiperazine, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
CZ224096A3 (en) 1997-02-12
KR970010746A (ko) 1997-03-27
AR004675A1 (es) 1999-03-10
SK100296A3 (en) 1997-03-05
US5731321A (en) 1998-03-24
ZA966552B (en) 1997-02-18
DE19528418A1 (de) 1997-02-06
CA2182469A1 (en) 1997-02-03
HUP9602127A1 (hu) 1998-05-28
BR9603252A (pt) 1998-04-28
PL315479A1 (en) 1997-02-03
JPH0940649A (ja) 1997-02-10
AU6079296A (en) 1997-02-06
NO963213L (no) 1997-02-03
HU9602127D0 (en) 1996-09-30
NO963213D0 (no) 1996-08-01
EP0757039A1 (de) 1997-02-05
AU705959B2 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
MX9701679A (es) Derivados de piperidina como antagonistas de la neuroquinina.
BG103485A (en) Ketobanzamides as calpain inhibitors
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MY117274A (en) Polycyclic amine compounds and their enantiomers,their method of preparation and pharmaceutical compositions in which they are present.
PL325339A1 (en) Derivatives of piperasine as neurokinin antagonists
SE9702773D0 (sv) Novel compounds
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
BG104916A (en) Calcilytic compounds
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
IL117209A0 (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
TR199900363T2 (xx) NK1 ve NK2 antagonistleri olarak asilaminoalkenilen-amid t�revleri.
BG105710A (en) 5ht1 antagonists for antidepressant therapy
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
BG105847A (en) Calcilytic compounds
MX9603199A (es) Antagonistas de receptores a endotelina.
BG103502A (en) Heterocyclic derivatives of carboxylic acids, their preparation and application as endothelial receptor antagonists
IL104485A0 (en) Benzimidazoles,their preparation and pharmaceutical compositions containing them
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
JO1999B1 (en) Isotopes of the hormone 'LH-RH' have their uses and the chemical compounds they contain
ZA983231B (en) Substituted benzyloxyimino compounds.
NZ516209A (en) Indoloazepines as vasopressin receptor antagonists
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
ES8505363A1 (es) Un procedimiento para preparar una 3-(2-furoil)-5-2,6-dimetil-4-(2-nitrofenil)-1,4-dihidropiridina